IC
MCRB icon

Ikarian Capital’s Seres Therapeutics MCRB Stock Holding History

Ikarian Capital’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$11.9M – 244
2021
Q2 		$11.9M Sell
25,000
-14,000
-36% -$5.91M 0.96% 28
2021
Q1 		$16.1M Buy
39,000
+21,945
+129% +$10.1M 0.54% 42
2020
Q4 		$8.36M Sell
17,055
-21,065
-55% -$12.3M 0.37% 66
2020
Q3 		$21.6M Buy
38,120
+25,620
+205% +$8.52M 1.56% 15
2020
Q2 		$1.19M Buy
+12,500
New +$1.1M 0.09% 118

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital's MCRB Position: Q4 2022 in Review

Ikarian Capital sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 6,566 shares — an estimated $843K sold.

Ikarian Capital first reported a position in MCRB in Q3 2020 and held it in 7 quarters. The position peaked at $7.21M in Q1 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Ikarian Capital reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ikarian Capital sold 6,566 Seres Therapeutics shares in Q4 2022, an estimated $843K.
  • Ikarian Capital first reported a position in Seres Therapeutics in Q3 2020 and held it in 7 quarters.
  • Ikarian Capital's Seres Therapeutics position peaked at $7.21M in Q1 2021.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Ikarian Capital's 13F filing for Q4 2022, filed 14 Feb 2023.